BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析

◆英語タイトル:BiondVax Pharmaceuticals Ltd (BVXV) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15060
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥39,900見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥79,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥119,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza strains; and pandemic influenza strains such as swine flu and avian flu. Its vaccine helps to provide multi-strain, multi season and long-term protection against various flu viruses. BiondVax Pharmaceuticals uses synthetic peptides in vaccines which offers practical advantages such as relative ease of production, chemical stability, and an avoidance of any infectious or oncogenic potential hazard. The company operates in Israel. BiondVax is headquartered in Ness Ziona, Israel.

BiondVax Pharmaceuticals Ltd Key Recent Developments

Nov 13,2018: BiondVax announces third quarter 2018 financial results
Nov 13,2018: BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
Oct 24,2018: BiondVax’s Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season’s Enrollment of 4,098 Participants
Oct 22,2018: BiondVax Receives 8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
Aug 22,2018: BiondVax Pharmaceuticals reports second quarter 2018 financial results

This comprehensive SWOT profile of BiondVax Pharmaceuticals Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of BiondVax Pharmaceuticals Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

BiondVax Pharmaceuticals Ltd – Key Information
BiondVax Pharmaceuticals Ltd – Overview
BiondVax Pharmaceuticals Ltd – Key Employees
BiondVax Pharmaceuticals Ltd – Key Employee Biographies
BiondVax Pharmaceuticals Ltd – Key Operational Heads
BiondVax Pharmaceuticals Ltd – Major Products and Services
BiondVax Pharmaceuticals Ltd – History
BiondVax Pharmaceuticals Ltd – Company Statement
BiondVax Pharmaceuticals Ltd – Locations And Subsidiaries
BiondVax Pharmaceuticals Ltd – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

BiondVax Pharmaceuticals Ltd – Business Description
BiondVax Pharmaceuticals Ltd – Corporate Strategy
BiondVax Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
BiondVax Pharmaceuticals Ltd – Strengths
BiondVax Pharmaceuticals Ltd – Weaknesses
BiondVax Pharmaceuticals Ltd – Opportunities
BiondVax Pharmaceuticals Ltd – Threats
BiondVax Pharmaceuticals Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

BiondVax Pharmaceuticals Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

BiondVax Pharmaceuticals Ltd, Key Information
BiondVax Pharmaceuticals Ltd, Key Ratios
BiondVax Pharmaceuticals Ltd, Share Data
BiondVax Pharmaceuticals Ltd, Major Products and Services
BiondVax Pharmaceuticals Ltd, History
BiondVax Pharmaceuticals Ltd, Key Employees
BiondVax Pharmaceuticals Ltd, Key Employee Biographies
BiondVax Pharmaceuticals Ltd, Key Operational Heads
BiondVax Pharmaceuticals Ltd, Other Locations
BiondVax Pharmaceuticals Ltd, Subsidiaries
BiondVax Pharmaceuticals Ltd, Key Manufacturing facilities
BiondVax Pharmaceuticals Ltd, Key Competitors
BiondVax Pharmaceuticals Ltd, SWOT Analysis
BiondVax Pharmaceuticals Ltd, Ratios based on current share price
BiondVax Pharmaceuticals Ltd, Annual Ratios
BiondVax Pharmaceuticals Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

BiondVax Pharmaceuticals Ltd, Performance Chart
BiondVax Pharmaceuticals Ltd, Ratio Charts

★海外企業調査レポート[BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Terme Catez D.D.:企業の戦略・SWOT・財務分析
    Terme Catez D.D. - Strategy, SWOT and Corporate Finance Report Summary Terme Catez D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alarko Contracting Group
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Outokumpu Oyj:企業のM&A・事業提携・投資動向
    Outokumpu Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Outokumpu Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact …
  • Amneal Pharmaceuticals Inc (AMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Amneal Pharmaceuticals Inc (Amneal) formerly Amneal Pharmaceuticals LLC, is an integrated specialty pharmaceutical company that produces generic, specialty and biosimilar medicines. Its product portfolio includes generic and specialty drugs in the therapeutic areas of analgesic, antibiotic, …
  • GenSight Biologics SA (SIGHT):製薬・医療:M&Aディール及び事業提携情報
    Summary GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company’s product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It d …
  • PeptiDream Inc (4587):企業の財務・戦略的SWOT分析
    Summary PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops constrained peptides, small molecule, and peptide-drug conjugate therapeutics. The company develops peptide discovery platform system (PDPS), a peptide generation and selection platform that helps to produ …
  • Blue Cross (Asia-Pacific) Insurance Limited:企業の戦略・SWOT・財務情報
    Blue Cross (Asia-Pacific) Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary Blue Cross (Asia-Pacific) Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • ING Life Insurance Company Korea, Ltd.:企業の戦略・SWOT・財務情報
    ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Yokohama City University-製薬・医療分野:企業M&A・提携分析
    Summary Yokohama City University (YCU) is an educational university that provides various undergraduate and graduate courses. The institute offers graduate program in various courses such as international management, nanobioscience, medical life science and medicine. It conducts research that contri …
  • Rexahn Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    Rexahn Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rexahn Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Physio-Control Inc-医療機器分野:企業M&A・提携分析
    Summary Physio-Control Inc (Physio-Control), a subsidiary of Bain Capital LLC is a medical device company that offers development, manufacturing, sale and service of emergency medical response products. The company provides pre-hospital, hospital, military, and accessory and disposable products. Its …
  • Advaxis Inc (ADXS):製薬・医療:M&Aディール及び事業提携情報
    Summary Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology that uses bioengineered live attenuated Listeria monocytogenes (Lm …
  • MAMEE-Double Decker (M) Sdn Bhd:企業の戦略的SWOT分析
    MAMEE-Double Decker (M) Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • NanoBio Corp-製薬・医療分野:企業M&A・提携分析
    Summary NanoBio Corp (NanoBio) is a biopharmaceutical company that develops vaccines. The company develops and commercializes intranasal and intramuscular vaccines for the prevention and treatment of infectious diseases. The company's vaccines include anthrax, H5 influenza, pertussis, RSV, HIV, HSV- …
  • China International Travel Service Corporation Limited:企業の戦略・SWOT・財務分析
    China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China International Travel Service Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Mindray Medical International Limited:企業の戦略・SWOT・財務情報
    Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report Summary Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Leon’s Furniture Ltd (LNF):企業の財務・戦略的SWOT分析
    Leon's Furniture Ltd (LNF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Valeura Energy Inc (VLE):企業の財務・戦略的SWOT分析
    Valeura Energy Inc (VLE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆